Phase I trial of an intranasal, nanoemulsion-adjuvanted herpes simplex virus-2 vaccine.
Phase of Trial: Phase I
Latest Information Update: 07 May 2018
At a glance
- Drugs Herpes simplex vaccine (Primary)
- Indications Herpes simplex virus type 2 infections
- Focus Adverse reactions
- Sponsors BlueWillow Biologics
- 07 May 2018 According to a BlueWillow Biologics media release, NanoBio Corporation has changed its name to BlueWillow Biologics.
- 02 May 2014 New trial record